Adverse event reporting and link and instructions for prescribing information can be found at the end of the letter.

SEPTEMBER 2025

ELVANSE® (lisdexamfetamine dimesylate), ONE DOSE RANGE for children, adolescents, and adults

Dear Healthcare Professional,

We are writing to inform you that the summary of product characteristics (SmPC), patient information leaflet (PIL) and packaging of Elvanse® (lisdexamfetamine dimesylate) and Elvanse Adult® (lisdexamfetamine dimesylate) **have been consolidated into one single range of doses under the brand, Elvanse®**.

This means that Elvanse is now licensed for use in patients aged 6 years and above, covering both children and adults:

- **Elvanse Adult is no longer available in the UK**
- Prescribers should now prescribe Elvanse for all eligible patients 6-years and above
- Pharmacies will only stock Elvanse, making supply simpler for both patients and healthcare professionals.

The consolidation of SmPC, PIL & packaging simplifies the Elvanse range, supporting availability for all Elvanse patients, streamlining choices on prescribing systems and reducing stockholding for pharmacists. No changes have been made to the formulation of Elvanse.

Takeda UK Limited
1 Kingdom Street
London
W2 6BD
United Kingdom

For reference, Takeda packaging for Elvanse doses is shown below. PIP codes for the single range remain the same as for the existing dose range of Elvanse:



How can I get support?

For questions relating to Takeda medicines, please contact your Takeda Account Lead or Takeda Medical Information Department:

medinfoEMEA@takeda.com
+44 (0)3333 000 181
Marketing Authorisation Holder
Takeda UK Limited

Elvanse is indicated for:

Elvanse is indicated for ADHD as part of a comprehensive treatment program for children (6 years and over) when response to methylphenidate is considered clinically inadequate and in adults with pre-existing childhood ADHD symptoms.

Treatment must be supervised by a specialist in behavioural disorders appropriate to the patient's age.

Elvanse is not indicated for all ADHD patients and the decision to use the medicinal product must consider the patient profile, including symptom severity, chronicity, potential for abuse, misuse or diversion, and clinical response to previous pharmacotherapies for ADHD.

Yours faithfully,

Takeda UK Limited

Takeda UK Limited
1 Kingdom Street
London
W2 6BD
United Kingdom

C-APROM/GB/NS/1439 | September 2025

Click or scan the QR code above to access Elvanse Prescribing Information

Adverse events should be reported to the Medicines and Healthcare products Regulatory Agency. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Takeda at:
AE.GBR-IRL@takeda.com.

Takeda UK Limited
1 Kingdom Street
London
W2 6BD
United Kingdom

C-APROM/GB/NS/1439 | September 2025